🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 91 of 857 · Phase 3 first, then by program name

  1. JNJ-73841937, Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung Carboplatin, JNJ-61186372, CARBOPLATIN , Carboplatin 10 mg/ml Intravenous Infusion, PEMETREXED

    Janssen-Cilag International N.V.

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. JNJ-75276617, Venclyxto 100 mg film-coated tablets, matching the 100 mg (G030), matching the 30 mg (G031), Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, JNJ-75276617, JNJ-75276617, matching the 50 mg (G029), JNJ-75276617, Azacitidine betapharm 25 mg/mL powder for suspension for injection

    Janssen-Cilag International N.V.

    Acute Myeloid Luekemia

    phase 3 small molecule active

    1 trial

  3. JNJ-77242113

    Janssen Cilag International NV

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  4. JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  5. JNJ-77242113, Film-Coated Tablet without JNJ-77242113, Film-Coated Tablet without Deucravacitinib, DEUCRAVACITINIB

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  6. JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  7. JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  8. JNJ-78278343, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, JNJ-78278343, Prednison acis 5 mg, Tabletten, DOCETAXEL , PREDNISONE

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  9. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  10. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Sjögren's Disease

    phase 3 small molecule active

    1 trial

  11. JNJ-90301900 (NBTXR3)

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Carcinoma, Squamous Cell

    phase 3 small molecule active

    1 trial

  12. JNT-517 Placebo, JNT-517, JNT-517

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  13. JPB898 (Induction and Maintenance)

    Sandoz Pty Ltd

    Melanoma

    phase 3 small molecule terminated

    1 trial

  14. JR-141

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  15. JR-141, Elaprase 2 mg/ml concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  16. JS001

    Shanghai University of Traditional Chinese Medicine

    Triple-Negative Breast Cancer

    phase 3 small molecule completed

    1 trial

  17. JX10, Jx10 placebo drug product is prepared as a sterile, lyophilized white to light yellow cake or powder for infusion.

    Lacuna Pharma Pty Ltd

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  18. JZP-110

    Jazz Pharmaceuticals Ireland Limited

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    3 trials

  19. JZP-110

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 3 small molecule completed

    3 trials

  20. JZP-258

    Jazz Pharmaceuticals Ireland Limited

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial

  21. JZP-258

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy With Cataplexy

    phase 3 small molecule completed

    1 trial

  22. JZP258

    Lacuna Pharma Pty Ltd

    Narcolepsy

    phase 3 small molecule active

    1 trial

  23. JZP598, GEMCITABINE , TRASTUZUMAB , CAPECITABINE , VINORELBINE , ERIBULIN

    Jazz Pharmaceuticals Ireland Limited

    Metastatic HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  24. Japanese encephalitis vaccine

    Sanofi Pasteur

    Japanese Encephalitis

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources